Specifically, vildagliptin was found to be able to decrease ALT, AST, and fatty liver (50 mg twice daily for 12 weeks, 58 NAFLD patients) [126] as well as hepatic triglycerides (50 mg twice daily for 6 months, 44 T2DM patients) [127]. Here, GPT is linked to Hepatic steatosis.